{"id":"W2127272421","doi":"10.1016/s0140-6736(12)60768-5","title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":1191,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Medical Research Council; Chest Heart and Stroke Scotland; National Health and Medical Research Council; Scottish Funding Council; Norges Forskningsråd; Dalhousie University; Schweizerische Herzstiftung; National Research Foundation; Karolinska Institutet; National Institute for Health and Care Research; University of Edinburgh; Stroke Association; Stockholms Läns Landsting; National Institute for Social Care and Health Research","keywords":"Thrombolysis; Ischaemic stroke; Medicine; Recombinant tissue plasminogen activator; Stroke (engine); Randomized controlled trial; Tissue plasminogen activator; Acute stroke; Clinical trial; Emergency medicine; Intensive care medicine; Internal medicine; Ischemic stroke; Ischemia; Myocardial infarction","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}